What Novo Nordisk's Earnings Reports Actually Reveal About GLP-1 Demand
Novo Nordisk breaks out sales for Ozempic, Wegovy, and Rybelsus in its quarterly filings. Here's how to read those numbers without over-interpreting them.
By the GLP Semaglutide editorial team · Last updated August 12, 2026
Novo Nordisk reports segment-level sales figures for its GLP-1 franchise in quarterly and annual filings, which analysts and journalists use as a proxy for real-world demand, manufacturing capacity, and market share against competitors like Eli Lilly.
What the numbers can and can't tell you
Reported sales reflect list price and volume trends, but they don't directly show prescription counts, out-of-pocket cost to patients, or shortage status — those require separate data sources like IQVIA prescription tracking or the FDA shortage database.
Where to check current figures
Novo Nordisk publishes its financial reports directly through its investor relations site. Figures cited in secondary news coverage, including this article, should be verified against the primary filing before being treated as current.
Primary sources